FutuRx
2 Ilan Ramon St., 3rd Floor, Ness Ziona, HaMerkaz, 7403635, Israel
Overview
FutuRx is the Israeli biotechnology accelerator that was established in 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation and Johnson & Johnson Development Corporation (JJDC) and Takeda Ventures Inc. following winning the tender of the Office of the Chief Scientist (OCS), Ministry of Economy, in Israel. The incubator will advance new biotechnology products by identifying and nurturing early-stage life science innovation. FutuRx is located in the Weizmann Science Park in Ness Ziona (near the Weizmann Institute), Israel.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 2
Sector focus
- Biotechnology
Investment portfolio
- Protekt Therapeutics
Participated · Equity · Nov 2019
ProteKt Therapeutics, based in Ness Ziona, Israel, develops potent and selective oral inhibitors of the kinase PKR for treatment of neurodegenerative and neuroinflammatory diseases. The company discovers molecules using unique computational methods and validates inhibitors in clinically relevant assays. ProteKt plans to select a lead drug candidate and validate its neurotherapeutic effects in vivo. It also intends to initiate clinical development of a related diagnostic assay for patient selection and treatment personalization. The company raised $3.6M in equity financing to support these development and validation activities. Led by CEO Yotam Nisemblat, ProteKt was founded by Carmel, Haifa University Economic Corporation and the Carmel Innovations Fund based on the research of Prof. Kobi Rosenblum and joined the FutuRx accelerator in 2015.